News
Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350) and CHF 600 million ...
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 ...
Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index ...
Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, ...
The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio’s ...
Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under ...
Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that the Alberta Securities Commission (the "ASC"), as its principal regulator, has revoked the management cease trade order ...
Patent Issuance: In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 by the U.S. Patent and Trademark Office, covering its SWAP™ technology for creating multi-specific Wnt surrogate molecules ...
Research and development expenses were $0.9 million for each of the three months ended June 30, 2025 and June 30, 2024, as an increase in EB06-related expenses for Edesa’s planned Phase 2 vitiligo ...
Net loss was $10,482,761, or ($0.39) per basic and diluted share attributable to common stockholders, for the six-month period ended June 30, 2025, compared to a net loss of $8,284,084, or ($0.38) per ...
Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil Lancement Officiel de la Commercialisation aux États-Unis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback